235 related articles for article (PubMed ID: 36291140)
1. Targeting Asparagine Synthetase in Tumorgenicity Using Patient-Derived Tumor-Initiating Cells.
Nishikawa G; Kawada K; Hanada K; Maekawa H; Itatani Y; Miyoshi H; Taketo MM; Obama K
Cells; 2022 Oct; 11(20):. PubMed ID: 36291140
[TBL] [Abstract][Full Text] [Related]
2. Metabolic Alterations Caused by KRAS Mutations in Colorectal Cancer Contribute to Cell Adaptation to Glutamine Depletion by Upregulation of Asparagine Synthetase.
Toda K; Kawada K; Iwamoto M; Inamoto S; Sasazuki T; Shirasawa S; Hasegawa S; Sakai Y
Neoplasia; 2016 Nov; 18(11):654-665. PubMed ID: 27764698
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic KRAS Regulates Amino Acid Homeostasis and Asparagine Biosynthesis via ATF4 and Alters Sensitivity to L-Asparaginase.
Gwinn DM; Lee AG; Briones-Martin-Del-Campo M; Conn CS; Simpson DR; Scott AI; Le A; Cowan TM; Ruggero D; Sweet-Cordero EA
Cancer Cell; 2018 Jan; 33(1):91-107.e6. PubMed ID: 29316436
[TBL] [Abstract][Full Text] [Related]
4. Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma.
Zhang B; Dong LW; Tan YX; Zhang J; Pan YF; Yang C; Li MH; Ding ZW; Liu LJ; Jiang TY; Yang JH; Wang HY
Br J Cancer; 2013 Jul; 109(1):14-23. PubMed ID: 23764751
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of asparagine synthetase (ASNS) suppresses cell proliferation and inhibits tumor growth in gastric cancer cells.
Yu Q; Wang X; Wang L; Zheng J; Wang J; Wang B
Scand J Gastroenterol; 2016 Oct; 51(10):1220-6. PubMed ID: 27251594
[TBL] [Abstract][Full Text] [Related]
6. Asparagine depletion potentiates the cytotoxic effect of chemotherapy against brain tumors.
Panosyan EH; Wang Y; Xia P; Lee WN; Pak Y; Laks DR; Lin HJ; Moore TB; Cloughesy TF; Kornblum HI; Lasky JL
Mol Cancer Res; 2014 May; 12(5):694-702. PubMed ID: 24505127
[TBL] [Abstract][Full Text] [Related]
7. [Relationship between asparagine synthetase expression level and cell sensitivity to L-asparaginase in human leukemic cell lines].
Li BS; He YY; Luo CY; Jiang H; Shen SH; Jiang LM; Zhang B; Gu LJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):559-63. PubMed ID: 20561401
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic tumor sensitivity to plasma L-asparagine starvation.
Dufour E; Gay F; Aguera K; Scoazec JY; Horand F; Lorenzi PL; Godfrin Y
Pancreas; 2012 Aug; 41(6):940-8. PubMed ID: 22513289
[TBL] [Abstract][Full Text] [Related]
9. Autophagic reliance promotes metabolic reprogramming in oncogenic KRAS-driven tumorigenesis.
Lin HH; Chung Y; Cheng CT; Ouyang C; Fu Y; Kuo CY; Chi KK; Sadeghi M; Chu P; Kung HJ; Li CF; Limesand KH; Ann DK
Autophagy; 2018; 14(9):1481-1498. PubMed ID: 29956571
[TBL] [Abstract][Full Text] [Related]
10. Low expression of asparagine synthetase in lymphoid blasts precludes its role in sensitivity to L-asparaginase.
Hermanova I; Zaliova M; Trka J; Starkova J
Exp Hematol; 2012 Aug; 40(8):657-65. PubMed ID: 22542578
[TBL] [Abstract][Full Text] [Related]
11. Tumoral microenvironment prevents de novo asparagine biosynthesis in B cell lymphoma, regardless of ASNS expression.
Grima-Reyes M; Vandenberghe A; Nemazanyy I; Meola P; Paul R; Reverso-Meinietti J; Martinez-Turtos A; Nottet N; Chan WK; Lorenzi PL; Marchetti S; Ricci JE; Chiche J
Sci Adv; 2022 Jul; 8(27):eabn6491. PubMed ID: 35857457
[TBL] [Abstract][Full Text] [Related]
12. Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines.
Lorenzi PL; Llamas J; Gunsior M; Ozbun L; Reinhold WC; Varma S; Ji H; Kim H; Hutchinson AA; Kohn EC; Goldsmith PK; Birrer MJ; Weinstein JN
Mol Cancer Ther; 2008 Oct; 7(10):3123-8. PubMed ID: 18852115
[TBL] [Abstract][Full Text] [Related]
13. Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells.
Lorenzi PL; Reinhold WC; Rudelius M; Gunsior M; Shankavaram U; Bussey KJ; Scherf U; Eichler GS; Martin SE; Chin K; Gray JW; Kohn EC; Horak ID; Von Hoff DD; Raffeld M; Goldsmith PK; Caplen NJ; Weinstein JN
Mol Cancer Ther; 2006 Nov; 5(11):2613-23. PubMed ID: 17088436
[TBL] [Abstract][Full Text] [Related]
14. Bisabosqual A: A novel asparagine synthetase inhibitor suppressing the proliferation and migration of human non-small cell lung cancer A549 cells.
Pan Y; Suzuki T; Sakai K; Hirano Y; Ikeda H; Hattori A; Dohmae N; Nishio K; Kakeya H
Eur J Pharmacol; 2023 Dec; 960():176156. PubMed ID: 38059445
[TBL] [Abstract][Full Text] [Related]
15. Promoter demethylation of the asparagine synthetase gene is required for ATF4-dependent adaptation to asparagine depletion.
Jiang J; Srivastava S; Seim G; Pavlova NN; King B; Zou L; Zhang C; Zhong M; Feng H; Kapur R; Wek RC; Fan J; Zhang J
J Biol Chem; 2019 Dec; 294(49):18674-18684. PubMed ID: 31659118
[TBL] [Abstract][Full Text] [Related]
16. Anticancer Properties of N,N-dibenzylasparagine as an Asparagine (Asp) analog, Using Colon Cancer Caco-2 Cell Line.
Mohamed EA; Bassiouny K; Alshambky AA; Khalil H
Asian Pac J Cancer Prev; 2022 Jul; 23(7):2531-2540. PubMed ID: 35901362
[TBL] [Abstract][Full Text] [Related]
17. Expression of asparagine synthetase predicts in vitro response to L-asparaginase in canine lymphoid cell lines.
Smallwood TL; Small GW; Suter SE; Richards KL
Leuk Lymphoma; 2014 Jun; 55(6):1357-65. PubMed ID: 24033105
[TBL] [Abstract][Full Text] [Related]
18. Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia.
Chan WK; Horvath TD; Tan L; Link T; Harutyunyan KG; Pontikos MA; Anishkin A; Du D; Martin LA; Yin E; Rempe SB; Sukharev S; Konopleva M; Weinstein JN; Lorenzi PL
Mol Cancer Ther; 2019 Sep; 18(9):1587-1592. PubMed ID: 31209181
[TBL] [Abstract][Full Text] [Related]
19. Utility of
Watanabe A; Miyake K; Yamada Y; Sunamura EI; Yotani T; Kagami K; Kasai S; Tamai M; Harama D; Akahane K; Goi K; Sakaguchi K; Goto H; Kitahara S; Inukai T
Epigenetics; 2023 Dec; 18(1):2268814. PubMed ID: 37839090
[TBL] [Abstract][Full Text] [Related]
20. Dual blockade of macropinocytosis and asparagine bioavailability shows synergistic anti-tumor effects on KRAS-mutant colorectal cancer.
Hanada K; Kawada K; Nishikawa G; Toda K; Maekawa H; Nishikawa Y; Masui H; Hirata W; Okamoto M; Kiyasu Y; Honma S; Ogawa R; Mizuno R; Itatani Y; Miyoshi H; Sasazuki T; Shirasawa S; Taketo MM; Obama K; Sakai Y
Cancer Lett; 2021 Dec; 522():129-141. PubMed ID: 34543685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
